article thumbnail

NGS is evolving: collaboration and tech lead the way

Drug Target Review

billion by 2029, a compound annual growth rate (CAGR) of approximately 13.2 The latest technologies are empowering researchers with faster, more efficient and more accessible genomic tools, leading to richer data generation and accelerating progress in areas like cancer genomics, rare disease research and infectious disease surveillance.​

RNA 92
article thumbnail

Biogen Launches Phase 3 Trial of Felzartamab for Primary Membranous Nephropathy

The Pharma Data

The trial is expected to complete in 2029. A Precision-Targeted Approach to an Unmet Need Felzartamab is a monoclonal antibody that targets CD38 , a protein found on plasma cells, which are responsible for producing the pathogenic autoantibodies in many immune-mediated diseases.

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Sun Has Started to Set on the Rare Pediatric Disease Priority Review Voucher Program – But It Can Still be Saved

FDA Law Blog: Drug Discovery

Although the earliest sunset of the year was actually in early December, this day also marked another premature sunset the beginning of the end of the rare pediatric disease priority review voucher program. As we blogged recently, the program has had scheduled sunset dates from its very beginning, which have been repeatedly extended.

Disease 59
article thumbnail

Organon drug for endometriosis falls short in mid-stage study

BioPharma Drive: Drug Pricing

The company had hoped to kick off Phase 3 research in 2026 and launch the medicine around 2029. Chief Executive Kevin Ali called the drug a “multibillion dollar opportunity” during the J.P. Morgan Healthcare Conference in January. Organon acquired the drug in its purchase of Forendo Pharma in 2021.

article thumbnail

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

FDA Law Blog: Biosimilars

Tobolowsky — The Rare Pediatric Disease Priority Review Voucher program has had a bit of a tumultuous history in its 12 short years of existence. Over 50 rare pediatric disease priority review vouchers have been awarded to date. We heard and felt the anxiety from many of our clients about the uncertainty this caused.

Disease 64
article thumbnail

Calico and Broad Institute extend collaboration, adding focus on age-related neurodegeneration

Broad Institute

Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery.

article thumbnail

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

The Pharma Data

“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About LATTICE-UC. About Ulcerative Colitis.

Disease 52